Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Primary Progressive Multiple Sclerosis: early-phase trial registry
1 of 3 indexed Primary Progressive Multiple Sclerosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Primary Progressive Multiple Sclerosis: 3 US clinical trials tracked, 1 recruiting.
Primary Progressive Multiple Sclerosis is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Tr1X, running 1 of these trials.
Enrollment posture brief
Registry condition primary-progressive-multiple-sclerosis
OPEN 1 | RECR 33% | LATE 1 | EARLY 2 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Primary Progressive Multiple Sclerosis lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Primary Progressive Multiple Sclerosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Primary Progressive Multiple Sclerosis is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
Tr1X
NCT07477639
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)
Sanofi
NCT04458051
Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00950248
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 3 | 1 |
Named interventions
Most-linked intervention names on Primary Progressive Multiple Sclerosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Primary Progressive Multiple Sclerosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Primary Progressive Multiple Sclerosis page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Primary Progressive Multiple Sclerosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Tr1X sponsors the most Primary Progressive Multiple Sclerosis trials on record, review their full trial history before evaluating a specific study. See Tr1X's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Primary Progressive Multiple Sclerosis condition card totals 3 registered trials; most-linked intervention Idebenone; top US site state Kansas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.